Ranbaxy announces settlement of possible Imitrex litigation with Glaxosmithkline
21 Jan 2008
Ranbaxy Laboratories Ltd has announced the settlement of "all matters relating to possible patent litigation with GlaxoSmithKline relating to Sumatriptan Succinate tablets", the generic version of GlaxoSmithKline's Imitrex tablets.
The terms of the settlement, provide that Ranbaxy may distribute a generic version of Sumatriptan Succinate tablets in the 25mg, 50mg and 100mg strengths in the United
States with an expected launch date in December 2008.
Additional terms of the settlement agreement were not disclosed.
The annual market sales for Sumatriptan Succinate (Imitrex) were $985 million (IMS- MAT: Sept 2007).